Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:35 AM
Ignite Modification Date:
2025-12-25 @ 12:35 AM
NCT ID:
NCT05572567
Eligibility Criteria:
Inclusion Criteria:
* Diagnosed with Rheumatoid Arthritis (RA) according to the 1987 American College of Rheumatology (ACR) or the ACR/European Lead Against Rheumatism (EULAR) 2010 RA Classification Criteria;
* At least 18 years of age or older;
* Was / Must be prescribed or switching to the following eligible medication for the first time ever at the enrollment visit:
* csDMARD: methotrexate (closed in February 2018);
* Anti-TNF bDMARD: adalimumab (originator or biosimilar), certolizumab pegol, etanercept (originator or biosimilar), golimumab, infliximab (originator or biosimilar), or any other anti-TNF biosimilar approved during the study;
* Non-TNF bDMARD: abatacept, tocilizumab, sarilumab (closed in June 2020);
* JAK inhibitor: tofacitinib, baricitinib, peficitinib, filgotinib, upadacitinib.
Exclusion Criteria:
* Data that are prior to March 2016 and after June 2022
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05572567
Study Brief:
Protocol Section:
NCT05572567